A comparative study in acute pancreatitis to find out the effectiveness of early addition of ulinastatin to current standard care in Indian subjects
Keywords:
Acute Pancreatitis, Ulinastatin, pain, inflammation, Ranson ScoreAbstract
Background: Acute pancreatitis is an inflammatory condition of the pancreas which begins in pancreatic acinar cells and triggers local inflammation that may progress to systemic inflammatory response (SIRS) causing distant organ involvement and hampering its function and ending up with multiple organ dysfunction syndrome (MODS). It remains a common disorder with devastating consequences .Although most episodes are mild and self-limiting, up to a one-fifth of patients develop a severe attack that can be fatal. Inspite of technical advances in medical and surgical field’s acute pancreatitis remains a major cause of morbidity and mortality. Aims and Objectives: Our aim is to find out the effectiveness of early addition of Ulinastatin to current standard care in Indian subjects with acute pancreatitis. The aim of this study is to compare effectiveness of with or without injection Ulinastatin in acute pancreatitis with respect to: 1) Duration of analgesic requirement, 2) Prevention of early sepsis and complication, 3) Duration of hospital stay. Material and methods: This prospective study was conducted between December 2018 to December 2019 on patients admitted to Dhiraj Hospital Piparia Vadodara. 60 patients with episodes of acute pancreatitis were enrolled for the study.
Downloads
References
Badalov N, Baradarian R, Iswara K, et al.Drug induced acute pancreatitis:An evidence based approach. ClinGastroenterolHepatol 20007101:454-76.
Shao Y Zhang L,DengL,YaoH.Clinical study on effects of Ulinastatin on patients with systemic inflammatory response syndrome.ChinCrit Care Med 2005 vol17 No4.Asian Pac. J. Health Sci., 2016; 3(4S):27-33e-ISSN: 2349-0659, p-ISSN: 2350-0964
NishiyamaT,YokoyamaT,YamashitaK.Effects of protease inhibitor ,Ulinastatin on coagulation and fibrinolysis in abdominal surgery.JAnesth 2006:20(3).
Abraham P et al: Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis. J Assoc Physicians India.2013;61(8):535-8.
Shi Yi-ni,et.al.Clinical study of the therapeutic value of the ulinastatin in systemic inflammatory response syndrome.China Chin J Crit Care Med.2004;24(1):1
JW Yoo et al:Preventive Effects of Ulinastatin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-Risk Patients: A Prospective, Randomized, Placebo-Controlled Trial.Pancreas.2008;37 (4):366-370
Grzegorz wallneret. Al . Morphological changes of the pancreas in course of acute pancreatitis during treatment with ulinastatin: PJS: 2013.85.3
R. Maciejewski et al. Serum amylase activity in experimental operated groups of the control value from unoperated animal course of experimental pancreatitis. Experimental and Toxicologic Pathology/2005; 56:305–311.
Ohwada M.et al: New endoscopic treatment for chronic pancreatitis, using contrast media containing ulinastatin and prednisolone.J Gastroenterol.1997; 32(2):216-21.
Chen YK, Tarnasky PR, Raijman I, et al. Peroral pancreatoscopy (PP) for pancreatic stone therapy and investigation of susptected pancreatic lesions: first human experience using the spyglass direct visualization system (SDVS) Gastrointest Endosc.2008;67:AB108.
Gress F, Schmitt C, Sherman S, Ciaccia D, Ikenberry S, Lehman G: Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience Am Gastroenterol.2001;96:409–416
Evaluation of therapeutic effectiveness of ulinastatinin acute pancreatitis: Syed Ibrahim Hassan*, 2Syed Mohd Akbar Hassan Asian Pac. J. Health Sci., 2016; 3(4S):27-3
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
